(Q35110104)

6 August 2017

1 reference

title

The role of T cells in psoriasis (English)

1 reference

6 August 2017

Prinz JC

1

1 reference

6 August 2017

1 May 2003

1 reference

Journal of the European Academy of Dermatology and Venereology

6 August 2017

1 reference

6 August 2017

17

1 reference

6 August 2017

3

1 reference

6 August 2017

257-270

1 reference

Psoriasis--epidemiology and clinical spectrum

6 August 2017

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-3083.2003.00720.X

Inflammatory skin diseases, T cells, and immune surveillance

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-3083.2003.00720.X

The immunologic and genetic basis of psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-3083.2003.00720.X

Which T cells cause psoriasis?

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-3083.2003.00720.X

Psoriasis: a T-cell-mediated autoimmune disease induced by streptococcal superantigens?

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-3083.2003.00720.X

Use of cyclosporin in psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-3083.2003.00720.X

Flow cytometric characterization of lesional T cells in psoriasis: intracellular cytokine and surface antigen expression indicates an activated, memory/effector type 1 immunophenotype.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-3083.2003.00720.X

Cutaneous lymphocyte antigen is a specialized form of PSGL-1 expressed on skin-homing T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-3083.2003.00720.X

The majority of epidermal T cells in Psoriasis vulgaris lesions can produce type 1 cytokines, interferon-gamma, interleukin-2, and tumor necrosis factor-alpha, defining TC1 (cytotoxic T lymphocyte) and TH1 effector populations: a type 1 differentiat

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-3083.2003.00720.X

Intralesional T-lymphocyte activation as a mediator of psoriatic epidermal hyperplasia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-3083.2003.00720.X

The pathogenesis of psoriasis: immunological facts and speculations

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-3083.2003.00720.X

The immune system. First of two parts

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-3083.2003.00720.X

Nuclear factor-kappaB: a pivotal transcription factor in chronic inflammatory diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-3083.2003.00720.X

Expression of HLA-DR molecules by keratinocytes, and presence of Langerhans cells in the dermal infiltrate of active psoriatic plaques

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-3083.2003.00720.X

Identification of a major susceptibility locus on chromosome 6p and evidence for further disease loci revealed by a two stage genome-wide search in psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-3083.2003.00720.X

Bacterial superantigens induce T cell expression of the skin-selective homing receptor, the cutaneous lymphocyte-associated antigen, via stimulation of interleukin 12 production.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-3083.2003.00720.X

Clonal characteristics of T cell infiltrates in skin and synovium of patients with psoriatic arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-3083.2003.00720.X

Mechanisms of antigen uptake for presentation

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-3083.2003.00720.X

Dendritic cells and the control of immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-3083.2003.00720.X

Cytokines and chemokines in the initiation and regulation of epidermal Langerhans cell mobilization

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-3083.2003.00720.X

The immune system. Second of two parts

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-3083.2003.00720.X

Isoforms of the transmembrane tyrosine phosphatase CD45 differentially affect T cell recognition.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-3083.2003.00720.X

Granzymes: exogenous proteinases that induce target cell apoptosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-3083.2003.00720.X

Perforin: structure and function

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-3083.2003.00720.X

T-cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-3083.2003.00720.X

ELAM-1 is an adhesion molecule for skin-homing T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-3083.2003.00720.X

CCL27-CCR10 interactions regulate T cell-mediated skin inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-3083.2003.00720.X

T-Cell Function and Migration — Two Sides of the Same Coin

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-3083.2003.00720.X

Effect of in vivo interleukin-1 on adhesion molecule expression in normal human skin

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-3083.2003.00720.X

21 January 2018

Cytokines in psoriasis.

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-3083.2003.00720.X

The Cytokine Network in Lesional and Lesion-Free Psoriatic Skin Is Characterized by a T-Helper Type 1 Cell-Mediated Response

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-3083.2003.00720.X

Functional diversity of helper T lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-3083.2003.00720.X

The expanding universe of T-cell subsets: Th1, Th2 and more.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-3083.2003.00720.X

Cytokines: IL-20 - a new effector in skin inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-3083.2003.00720.X

Injection of pre-psoriatic skin with CD4+ T cells induces psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-3083.2003.00720.X

CD4 antibody treatment of severe psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-3083.2003.00720.X

Effects of administration of a single dose of a humanized monoclonal antibody to CD11a on the immunobiology and clinical activity of psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-3083.2003.00720.X

Dermatologic complications of HIV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-3083.2003.00720.X

PUVA bath therapy strongly suppresses immunological and epidermal activation in psoriasis: a possible cellular basis for remittive therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-3083.2003.00720.X

Specific interaction of lymphocyte function-associated antigen 3 with CD2 can inhibit T cell responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-3083.2003.00720.X

Treatment of chronic plaque psoriasis by selective targeting of memory effector T lymphocytes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-3083.2003.00720.X

Eruptive syringoma: 27 new cases and review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-3083.2003.00720.X

SELECTIVE DELETION OF ANTIGEN-SPECIFIC, ACTIVATED T CELLS BY A HUMANIZED MAB TO CD2 (MEDI-507) IS MEDIATED BY NK CELLS

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-3083.2003.00720.X

Blockade of T lymphocyte costimulation with cytotoxic T lymphocyte-associated antigen 4-immunoglobulin (CTLA4Ig) reverses the cellular pathology of psoriatic plaques, including the activation of keratinocytes, dendritic cells, and endothelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-3083.2003.00720.X

Interleukin 10 treatment of psoriasis: clinical results of a phase 2 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-3083.2003.00720.X

Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-3083.2003.00720.X

Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-3083.2003.00720.X

Review article: safety of infliximab in clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-3083.2003.00720.X

Demyelination occurring during anti-tumor necrosis factor alpha therapy for inflammatory arthritides

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-3083.2003.00720.X

Immunotherapy with Mycobacterium vaccae in the treatment of psoriasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-3083.2003.00720.X

Macrolactam immunomodulators for topical treatment of inflammatory skin diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-3083.2003.00720.X

The ascomycin macrolactam pimecrolimus (Elidel, SDZ ASM 981) is a potent inhibitor of mediator release from human dermal mast cells and peripheral blood basophils

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-3083.2003.00720.X

Mycobacterium vaccae in immunoprophylaxis and immunotherapy of leprosy and tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-3083.2003.00720.X

Invasive Pulmonary Aspergillosis Associated with Infliximab Therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-3083.2003.00720.X

10.1046/J.1468-3083.2003.00720.X

21 January 2018

Identifiers

DOI

1 reference

6 August 2017

1 reference

PubMed ID

12702062